Glaxosmithkline Pharmaceuticals Ltd
₹2594.40
(-2.78%)
Fri, 13 Feb 2026, 01:14 pm
Health Technology
Pharmaceuticals: Major
24.5KGlaxosmithkline Pharmaceuticals Price to Cash Flow Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 30.84 | 26.86 | 21.30 | 20.99 | 27.25 | 34.31 | 26.06 | 32.65 | 52.62 | 77.72 | 85.58 | 68.79 | 50.36 | 49.44 | 226.34 | 68.13 | 16.62 | 36.73 | 55.80 | 52.55 |
| Price to book ratio | 9.96 | 8.19 | 6.32 | 6.17 | 7.64 | 10.17 | 8.47 | 9.14 | 12.74 | 15.76 | 14.75 | 11.54 | 8.59 | 10.29 | 11.59 | 16.51 | 10.58 | 12.88 | 18.52 | 24.98 |
| Price to sales ratio | 6.39 | 6.23 | 5.46 | 5.77 | 7.15 | 9.01 | 6.75 | 6.85 | 9.94 | 10.96 | 11.72 | 7.97 | 6.15 | 7.04 | 6.54 | 8.34 | 8.59 | 6.90 | 9.53 | 13 |
| Price to cash flow ratio | 25 | 33.22 | 22.30 | 23.29 | 22.26 | 35.68 | 35 | 38.66 | 55.81 | 55.80 | 114.58 | 72.50 | 32.96 | 46.31 | 38.01 | 38.58 | 32.97 | 40.99 | 48.75 | 34.62 |
| Enterprise value | 95.7B | 98.33B | 85.75B | 87.64B | 119.09B | 178.4B | 143.6B | 162.32B | 233.01B | 269.14B | 308.03B | 222.7B | 163.69B | 208.49B | 200.54B | 232.78B | 253.41B | 207.73B | 310.57B | 462.29B |
| Enterprise value to EBITDA ratio | 21.73 | 20.07 | 15.54 | 15.03 | 17.64 | 22.91 | 17.81 | 19.99 | 44.45 | 54.59 | 61.43 | 51.73 | 31.16 | 33.87 | 29.47 | 38.46 | 32.81 | 25.31 | 33.93 | 38.86 |
| Debt to equity ratio | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| Return on equity % | 33.21 | 34.03 | 31.68 | 31.31 | 29.77 | 30.94 | 32.38 | 28.51 | 24.11 | 19.43 | 18.75 | 16.08 | 17.26 | 21.22 | 4.71 | 17.42 | 18.30 | 27.59 | 33.53 | 49.75 |
Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio
The Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio is a key financial metric used by investors to evaluate Glaxosmithkline Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Glaxosmithkline Pharmaceuticals Ltd (NSE: GLAXO, BSE: 500660) is currently trading at ₹2594.40, with a market capitalization of ₹451.8B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio is essential for fundamental analysis.
Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio Current Value
The current Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio stands at 34.62.
The Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio Historical Trend
The Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio has shown the following historical trend:
- 2024: 34.62
- 2023: 48.75
- 2022: 40.99
- 2021: 32.97
- 2020: 38.58
The decline in Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio indicates improving financial efficiency or better earnings growth.
What Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio Indicates for Investors
The Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/CF ratio indicates how much investors pay for company cash flow.
Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio Analysis Summary
The Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800